Skip to content

Using GLP-1s

Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration

Missed a few weeks of Wegovy, Zepbound, Ozempic, Trulicity, Saxenda, or a GLP-1 pill? Only four labels spell out when to restart at a lower dose: Wegovy injection after 2 missed weekly doses, Saxenda and Victoza after more than 3 days, and Foundayo after 7 missed daily doses. The rest are silent on long gaps. This by-drug reference separates what each label says from what's left to your prescriber, and explains why going straight back to your old dose is risky.

By the glp1.how editorial teamReviewed 7 min read

Evidence-backed

In 2026, surgeons described a woman in her 50s who restarted semaglutide at the full 2.4 mg weekly dose after several months off. She hadn't stepped back up through the doses. The next day she developed severe nausea and vomiting and a torn esophagus, which her surgeons thought the vomiting likely caused, and she spent months recovering (Aubrey et al., Journal of Cardiothoracic Surgery, 2026, DOI (external link)). That outcome is very rare. Going straight back to your old dose after a break is an easy mistake to make, though.

This guide is a by-drug reference for one question: what does each medication's FDA label say about restarting after a gap? It keeps two things apart: what the label actually says, and what's left to your prescriber's judgment. For a single late or forgotten dose, see what to do if you miss a GLP-1 dose. For the bigger picture on coming off, including weight regain, see stopping a GLP-1.

Why a gap resets your tolerance

GLP-1 doses start low and climb in steps because the stomach side effects (nausea, vomiting, diarrhea) are worst when the dose rises. Over weeks at each step, your body adapts. See how titration schedules work.

Stop taking the drug and it leaves your system at a rate set by its half-life. Once enough of it is gone, a full dose hits more like a first dose than a routine one. That's why the labels that do address long gaps say to restart lower. For example, the Wegovy label says to restart the dose climb "to reduce the risk of gastrointestinal adverse reactions."

The half-lives differ a lot, which helps explain why the labels' thresholds do too:

MedicationApproximate half-life (FDA label)
Semaglutide (Wegovy, Ozempic, and the semaglutide pills)About 1 week
Tirzepatide (Zepbound, Mounjaro)About 5 days
Dulaglutide (Trulicity)About 5 days
Orforglipron (Foundayo)About 29 to 49 hours
Liraglutide (Saxenda, Victoza)About 13 hours

What each label says

The table below reflects each drug's US prescribing information as of September 2026. "No instruction" means the label only covers a single missed dose. It does not mean resuming your old dose after a long gap is safe.

MedicationOne missed dose (label)Longer gap: what the label says about restarting
Wegovy injection (semaglutide, weekly)Take it as soon as possible if your next dose is more than 2 days (48 hours) away. If it's less than 2 days away, skip it and keep your usual day.If 2 or more doses in a row are missed, restart the dose escalation at a lower dose. The patient information says to contact your provider about how to restart.
Wegovy pill (oral semaglutide, daily)Skip it and take the next dose the following day.No instruction for longer gaps.
Ozempic injection (semaglutide, weekly)Take it within 5 days of the missed dose. After more than 5 days, skip it and take the next dose on your usual day.No instruction for longer gaps.
Ozempic tablets / Rybelsus (oral semaglutide, daily)Skip it and take the next dose the following day.No instruction for longer gaps.
Zepbound and Mounjaro (tirzepatide, weekly)Take it within 4 days (96 hours). After more than 4 days, skip it and take the next dose on your usual day. Keep doses at least 3 days (72 hours) apart.No instruction for longer gaps.
Trulicity (dulaglutide, weekly)Take it if at least 3 days (72 hours) remain before your next dose. Otherwise skip it.No instruction for longer gaps.
Saxenda (liraglutide, daily)Skip it and resume with your next scheduled dose. Don't take extra.If more than 3 days have passed since your last dose, restart at 0.6 mg a day and follow the dose escalation again. The patient information says to call your provider after 3 or more missed days.
Victoza (liraglutide, daily)Skip it and resume with your next scheduled dose. Don't take extra.If more than 3 days have passed since your last dose, restart at 0.6 mg a day, then increase at your provider's discretion.
Foundayo (orforglipron, daily)Take it as soon as possible. Don't take two doses in the same day.If 7 or more doses in a row are missed, restart the dose escalation at a lower dose. The patient information says to call your provider after 7 or more missed days in a row.

Three things stand out.

  1. Only four labels give a restart rule: Wegovy injection, Saxenda, Victoza, and Foundayo. Two weeks for Wegovy, three days for liraglutide, and seven days for Foundayo. The shorter the half-life, the shorter the gap before the label wants you to start lower.
  2. Where there is a rule, the label mostly doesn't name the restart dose. Wegovy and Foundayo say "a lower dosage" without saying which one. Only Saxenda and Victoza name a dose (0.6 mg). Picking the step is left to your prescriber.
  3. Most labels are silent on long gaps. Ozempic, Zepbound, Mounjaro, Trulicity, and the semaglutide pills explain what to do about one missed dose, then stop.

If you've been through a Wegovy restart before, note that the current wording is firmer than some older descriptions. The label now says to restart at a lower dose after 2 or more consecutive missed doses; it doesn't present resuming your usual dose as an alternative.

When the label is silent

A label saying nothing about a long gap doesn't make the gap harmless. The drug's half-life, and your tolerance, work the same way whatever the label says. Several published case reports show what can happen when people restart at their previous dose after a break:

  • A 33-year-old man restarted weekly semaglutide at his target dose after a seven-week gap caused by a prior-authorization lapse and had recurrent nausea and vomiting needing medical treatment. The pharmacists who reported it suggested that a lapse, "typically defined as missing three or more doses of a once-weekly injectable," warrants considering a lower restart dose, tailored to how well you tolerated the drug before, your goals, and how long you were off (Denny et al., Journal of Pharmacy Practice, 2024, DOI (external link)).
  • A 70-year-old woman missed two weekly doses of dulaglutide during a hospital stay, was restarted at 4.5 mg on discharge, and was readmitted with gastritis. Her pharmacists called for clearer guidance on restarting after missed doses in hospital (Michelet et al., Hospital Pharmacy, 2025, DOI (external link)).
  • A 51-year-old woman who had taken semaglutide 2.4 mg for about a year paused for five weeks during Ramadan, restarted at 2.4 mg, and was hospitalized for four days with severe vomiting, diarrhea, and electrolyte problems (Valizada and Zilbermint, Cureus, 2026, DOI (external link)).
  • An older patient developed severe GI symptoms and systemic complications within hours of restarting high-dose semaglutide after a prolonged break (Mehta et al., Clinical Case Reports, 2026, DOI (external link)).

These are individual cases, not trials. They can't tell you how often this happens or what the "right" restart dose is, and nobody has run a trial to answer that. What they show is that the risk is real, and that it can follow gaps of only a few weeks.

Label rules vs. clinical practice

The label is the official instruction, but it's partial: most labels don't address long gaps, and only Saxenda and Victoza name a restart dose. Case reports and pharmacist proposals, such as considering a lower restart after three or more missed weekly doses, are useful warning signs, not tested rules. The actual decision gets made by your prescriber, based on your gap, your old dose, and how titration went the first time.

When you ask about restarting, expect your prescriber to weigh:

  • How long you've been off, counted from your last dose.
  • What dose you were on, and how many steps it took to get there.
  • How the first titration went. If you had a rough time early on, a more cautious restart makes sense.
  • Why you stopped. A supply gap is different from stopping because of side effects.
  • Other medications, especially insulin or a sulfonylurea if you have diabetes. The labels warn that combining a GLP-1 with these raises the risk of low blood sugar, and doses may have been changed while you were off.

A restart may mean going back to the lowest dose, or dropping back a step or two and climbing faster than the first time. That's a clinical call, not something the labels settle.

Practical tips

  • Count your gap in doses and days, then check it against the table for your drug.
  • Don't use leftover higher-dose pens or tablets to restart unless your prescriber tells you to. A lower restart dose usually means a new prescription for a lower-strength pen or tablet, so ask before the gap ends.
  • Have your nausea plan ready. The side-effect advice from your first weeks applies again: see managing nausea and our GI side effects overview. Persistent vomiting can lead to dehydration and kidney injury, so don't wait it out.
  • Never double up to "catch up" on doses you missed. If it's already happened, see what to do after an accidental double dose.
  • Stretching doses on purpose is different from missing them. If you've been spacing injections out deliberately, see stretching your dose past 7 days.

If you've missed more than a dose or two, call your prescriber or pharmacist before your next dose, and restart on a plan.


Label details come from each medication's FDA prescribing information current as of September 2026, and labels change, so check the patient information that comes with your prescription. Case reports above are attributed to their authors and were located via PubMed. This guide is general education, not medical advice. Your restart dose is a decision for you and your prescriber.

restartingre-titrationmissed-dosedosingtitrationwegovyozempiczepboundmounjarotrulicitysaxendavictozafoundayooral-glp1

Common questions

Questions people often ask about this topic.

  • I missed two weeks of Wegovy. Can I restart at my usual dose?

    The Wegovy injection label says no: if 2 or more doses in a row are missed, restart the dose escalation at a lower dose to reduce the risk of gastrointestinal side effects. The label doesn't say which lower dose, so contact your prescriber about how to restart, as the patient information advises.

  • What does the Zepbound or Mounjaro label say about restarting after several missed weeks?

    Nothing specific. Both tirzepatide labels cover a single missed dose (take it within 4 days, otherwise skip it) and don't give a rule for longer gaps. That silence isn't permission to go straight back to your old dose: tirzepatide has a half-life of about 5 days, and published cases show people restarting at full dose after a few weeks off ending up with severe nausea and vomiting. Ask your prescriber for a restart plan.

  • How many days can I miss Saxenda or Victoza before I have to start over?

    Three. Both liraglutide labels say that if more than 3 days have passed since your last dose, restart at 0.6 mg a day and work back up. Liraglutide has a half-life of about 13 hours, so tolerance fades faster than with the weekly drugs.

  • What if I miss several days of a GLP-1 pill?

    It depends on the pill. The Foundayo label says that if 7 or more daily doses in a row are missed, restart the dose escalation at a lower dose. The semaglutide pills (Wegovy pill, Ozempic tablets, Rybelsus) only say to skip a missed dose and take the next one the following day; they don't address longer gaps. After more than a few days off any GLP-1, check with your prescriber before resuming.

  • If my drug's label doesn't mention restarting, is it safe to resume my old dose?

    Not necessarily. Most labels (Ozempic, Zepbound, Mounjaro, Trulicity, and the semaglutide pills) only cover a single missed dose. Tolerance still fades as the drug clears, and case reports describe hospitalizations after people restarted full doses following gaps of two to seven weeks. One pharmacist report suggested considering a lower restart dose once three or more weekly doses are missed. The restart dose is a decision for your prescriber.

  • Will I have to go all the way back to the starting dose?

    Not always. Only the Saxenda and Victoza labels name a restart dose (0.6 mg). The Wegovy and Foundayo labels say only 'a lower dosage,' and the other labels say nothing. Your prescriber may restart you at the bottom or a step or two below your old dose, depending on how long you were off, what dose you were on, and how you tolerated titration the first time.

Evidence

The sources behind this article, labeled by type and strength.

Supporting9

Mixed findings6

Revision history

Updated 4 times since Sep 26, 2026 · show changes
  1. v5

    Summary rewritten; Body revised

  2. v4

    Published

  3. v3

    Common questions 0 → 6

  4. v2

    Evidence sources 0 → 15

  5. v1

    First version

Related guides

  • Switching from a GLP-1 injection to a pill to keep the weight off: what the first trial found · If you've lost weight on Zepbound or Wegovy and want off the weekly injection, can a daily pill hold your results? One randomized trial has now tested exactly that, and Wegovy users also have an on-label switch to Wegovy tablets. This guide covers what the trial found, how much weight people kept, what the switch felt like, and the big question the trial didn't answer.
  • Liraglutide (Victoza and Saxenda): how the daily GLP-1 differs · Liraglutide (Victoza for diabetes, Saxenda for weight) was the first GLP-1 approved for weight management. It's a daily injection with a half-life of about 13 hours and generally more modest weight loss than the weekly drugs. What makes it different, and why some people still choose it.
  • Stopping a GLP-1: tapering, weight regain, and restarting safely · Whether by choice or circumstance, most people stop a GLP-1 at some point. This guide covers what stopping can and can't get you, what withdrawal trials and real-world data show about weight regain and lost health benefits, whether a GLP-1 is really a medication for life, how tapering compares, and why restarting after a gap usually means re-titrating.
  • When and why a prescriber might slow down your titration · You can stay at a dose step longer than the standard titration schedule says. This guide covers what the labels allow, the common reasons prescribers extend a step, and how to raise it.
  • What to do if you miss a GLP-1 dose · Missed-dose rules depend on how close you are to your next scheduled dose and on the drug, and getting it wrong in either direction carries real risk. The label rules for weekly injections, daily injections and pills, and when a missed dose means restarting lower.
  • What "maintenance dose" actually means and how it's decided · Your maintenance dose is the dose that works for you, which isn't always the highest dose on the label. This guide explains how that dose gets chosen, what the trials show about higher and lower maintenance doses, and when it can change.

Related terms

  • Semaglutide · A GLP-1 receptor agonist medication made by Novo Nordisk, sold under the brand names Ozempic (type 2 diabetes) and Wegovy (weight management), each as an injection or a pill.
  • Weight regain · The return of lost weight, commonly seen after stopping a GLP-1 medication.
  • GLP-1 · A gut hormone (glucagon-like peptide-1) that stimulates insulin release, slows digestion, and reduces appetite; the target of drugs like semaglutide and liraglutide.
  • Half-life · The time it takes for half of a drug dose to be cleared from the body — determines how often a medication needs to be taken.
  • Wegovy · Novo Nordisk's brand name for semaglutide (weekly injection or, since December 2025, a daily pill), FDA-approved for chronic weight management and heart-risk reduction, and as an injection for MASH liver disease.
  • Ozempic · Novo Nordisk's brand name for semaglutide for type 2 diabetes, sold as a weekly injection and, since May 2026 in the US, as daily Ozempic tablets.
  • Tirzepatide · A once-weekly dual GIP and GLP-1 receptor agonist made by Eli Lilly, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management and obstructive sleep apnea.
  • Zepbound · Eli Lilly's brand name for injectable tirzepatide, FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity.

Was this helpful?

Improve this page